The chronic myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF), are frequently characterized by the JAK2 mutations [122,123]. This evidence concerns the gene JAK2 and essential thrombocythemia.